Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)

3.22
Delayed Data
As of 3:59pm ET
 -0.28 / -8.00%
Today’s Change
2.55
Today|||52-Week Range
8.83
-46.69%
Year-to-Date
Zynerba Pharmaceuticals (ZYNE) Investor Presentation - Slideshow
Sep 18 / Seeking Alpha - Paid Partner Content
Zynerba's cannabidiol an Orphan drug for a rare chromosomal disorder
Sep 17 / Seeking Alpha - Paid Partner Content
Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7.7%
Sep 18 / Zacks.com - Paid Partner Content
Zynerba Pharmaceuticals provides update on recent milestones
Sep 14 / Seeking Alpha - Paid Partner Content
Making The Case For Zynerba Pharmaceuticals
Sep 17 / Seeking Alpha - Paid Partner Content
 

Today’s Trading

Previous close3.50
Today’s open3.47
Day’s range3.20 - 3.50
Volume33,246
Average volume (3 months)1,405,164
Market cap$108.2M
Data as of 3:59pm ET, 09/23/2020

Growth & Valuation

Earnings growth (last year)+42.56%
Earnings growth (this year)-41.62%
Earnings growth (next 5 years)--
Revenue growth (last year)-100.00%
P/E ratioNM
Price/Sales--
Price/Book1.14

Competitors

 Today’s
change
Today’s
% change
LPCNLipocine Inc-0.14-8.77%
--Ecogreen Internation...-0.00-0.76%
AIMAIM ImmunoTech Inc-0.29-11.42%
CAPRCapricor Therapeutic...-0.19-3.60%
Data as of 4:03pm ET, 09/23/2020

Financials

Next reporting dateNovember 17, 2020
EPS forecast (this quarter)-$0.43
Annual revenue (last year)$0.00
Annual profit (last year)-$32.9M
Net profit margin--

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
No executives to display
Corporate headquarters
Devon, Pennsylvania

Forecasts